- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07777068
Ejaculation-Preserving Versus Conventional Dual Wavelength Diode Laser Vaporization of the Prostate (EP-TUVP)
Ejaculation-Preserving Versus Conventional Dual-Wavelength Diode Laser Vaporization of the Prostate: A Randomized Comparative Study With 12-Month Follow up
Surgery to relieve urinary blockage caused by an enlarged prostate works well, but most men lose antegrade ejaculation afterwards, because semen passes backwards into the bladder instead of forwards. For sexually active men this is an important concern and a common reason for delaying or refusing surgery.
This study compared two ways of performing the same operation, laser vaporization of the prostate using a dual-wavelength diode laser. In the conventional technique, prostate tissue is removed from the bladder neck all the way to the verumontanum. In the ejaculation-preserving technique, the surgeon deliberately leaves a 10 mm rim of tissue at the bladder neck untouched, and another 10 mm of tissue just before the verumontanum untouched, while removing the blocking tissue in between. Everything else about the operation, including the laser settings, was the same.
Men were assigned to one of the two techniques by a computer-generated random sequence. They were assessed before surgery and again at 7 to 14 days, 1 month, 3 months, 6 months and 12 months after surgery.
The main question was how many men still had antegrade ejaculation 3 months after surgery. The study also compared urinary symptoms, urine flow rate, residual urine volume, prostate size, erectile function, complications and patient satisfaction, to find out whether preserving ejaculation costs anything in terms of relieving the urinary blockage.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
BACKGROUND
Loss of antegrade ejaculation follows conventional transurethral resection or vaporization of the prostate in the majority of men. Two anatomical regions are considered central to this: the internal urethral sphincter at the bladder neck, which prevents retrograde passage of semen, and the paracollicular and supracollicular tissue around the verumontanum, which contributes to the emission phase. Techniques preserving one or both regions have been described across several endoscopic platforms, but evidence specific to the dual-wavelength diode laser is limited and follow-up in previous work has been short.
OBJECTIVE
To determine whether an ejaculation-preserving technique of dual-wavelength diode laser vaporization of the prostate preserves antegrade ejaculation without compromising relief of bladder outlet obstruction, and whether any benefit is durable to 12 months.
DESIGN
Prospective, randomized, single-centre comparative study conducted at the Department of Urology, Royal Hospital, Sulaymaniyah, Kurdistan Region, Iraq. Allocation followed a computer-generated random sequence, with assignments concealed in sequentially numbered opaque sealed envelopes opened after consent. Participants were not informed of their allocation. The operating surgeon was necessarily aware of allocation.
INTERVENTION
All procedures were performed by a single surgeon under spinal or general anaesthesia, using a 22 Fr continuous-flow laser cystoscope sheath with normal saline irrigation. Energy was delivered by a Ceralas dual-wavelength diode laser system (biolitec biomedical technology GmbH, Jena, Germany) emitting simultaneously at 980 nm and 1470 nm, through a bare-tip fibre in continuous-wave mode at a total power of 140 W. Laser wavelength, fibre type, emission mode and power setting were identical in both arms.
Conventional arm: vaporization proceeded from the bladder neck to the verumontanum in the standard fashion, including tissue at the bladder neck and immediately proximal to the verumontanum, until a wide channel was created.
Ejaculation-preserving arm: no vaporization was performed within 10 mm distal to the bladder neck, and no vaporization was performed within 10 mm proximal to the verumontanum. Between these two margins, the lateral lobes, median lobe and anterior tissue were vaporized to the same endpoint as in the conventional arm. Adherence to both margins was recorded prospectively in every case.
ASSESSMENTS
Participants were assessed at baseline and at day 7 to 14, 1 month, 3 months, 6 months and 12 months. Symptoms were quantified with the International Prostate Symptom Score and its quality-of-life item, and erectile function with the five-item International Index of Erectile Function. Uroflowmetry was accepted only with a voided volume of at least 150 mL. Post-void residual volume and prostate volume were measured by transabdominal ultrasound. Ejaculatory status was recorded as a binary patient-reported outcome: presence or absence of any antegrade ejaculate during sexual activity since the preceding visit. Complications were graded using the Clavien-Dindo classification.
ANALYSIS
Continuous variables were compared between arms with the Mann-Whitney U test and within arms against baseline with the Wilcoxon signed-rank test. Proportions were compared with the two-sided Fisher exact test, with risk differences reported using Newcombe hybrid-score 95 percent confidence intervals. No imputation was performed. Analysis was restricted to participants with complete records at every scheduled visit.
NOTE ON REGISTRATION
This trial was registered retrospectively. The protocol, including the primary endpoint, the secondary endpoints and the two 10 mm technical margins, was submitted to and registered by the Scientific Committee of the Department of Clinical Sciences, College of Medicine, University of Sulaimani (number 28, 25 February 2025) and approved by the Ethics Committee of the same institution (number 62, 2 March 2025). Public registry registration was not undertaken before enrolment because the requirement was not appreciated at the time. No outcome measures, eligibility criteria or analysis definitions were altered after the study began.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Kurdistan
-
Sulaymaniyah, Kurdistan, Irak, 46001
- Royal Hospital, Department of Urology
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Male, aged 50 years or older
- Lower urinary tract symptoms attributable to benign prostatic obstruction
- International Prostate Symptom Score of 16 or more
- Maximum urinary flow rate below 15 mL/s on a uroflowmetry study with a voided volume of at least 150 mL
- Prostate volume between 30 and 150 cc on transabdominal ultrasound
- Indication for surgery after failure of or intolerance to medical therapy
- Preserved antegrade ejaculation at baseline
- Currently sexually active
- Willing and able to attend all scheduled follow-up visits
- Written informed consent, including specific consent to discussion and recording of ejaculatory function
Exclusion Criteria:
- Suspected or confirmed prostate cancer
- Prostate-specific antigen above the age-specific reference range without a benign explanation
- Neurogenic bladder
- Urethral stricture
- Bladder stones
- Previous prostatic or urethral surgery
- Absent antegrade ejaculation at baseline
- Erectile dysfunction sufficient to preclude sexual activity
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: conventional tuvp
Conventional dual-wavelength diode laser vaporization of the prostate.
Vaporization proceeded from the bladder neck to the verumontanum in the standard fashion, with removal of obstructing adenoma including the tissue at the bladder neck and immediately proximal to the verumontanum, until a wide channel was created
|
Transurethral vaporization of the prostate using a Ceralas dual-wavelength diode laser (biolitec biomedical technology GmbH, Jena, Germany) emitting simultaneously at 980 nm and 1470 nm, bare-tip fibre, continuous wave, total power 140 W, delivered through a 22 Fr continuous-flow laser cystoscope sheath with normal saline irrigation, under spinal or general anaesthesia.
Adenoma was vaporized from the bladder neck to the verumontanum without preservation margins.
|
|
Expérimental: Ejaculation-Preserving TUVP (EP-TUVP)
Ejaculation-preserving dual-wavelength diode laser vaporization of the prostate.
No vaporization was performed within 10 mm distal to the bladder neck, preserving the circular muscle fibres of the internal sphincter, and no vaporization was performed within 10 mm proximal to the verumontanum, preserving the paracollicular and supracollicular tissue.
Between these two margins, the lateral lobes, median lobe and anterior tissue were vaporized to the same endpoint as in the conventional arm.
Laser settings were identical to the comparator arm.
|
Identical equipment, laser settings and anaesthesia to the comparator intervention, with two preservation margins: no vaporization within 10 mm distal to the bladder neck and none within 10 mm proximal to the verumontanum.
Adequacy of the mid-prostatic channel was confirmed endoscopically at the end of the procedure.
Adherence to both margins was recorded prospectively for every case.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Preservation of antegrade ejaculation
Délai: 3 months after surgery
|
Proportion of participants reporting the presence of any antegrade ejaculate during sexual activity since the preceding visit.
Recorded as a binary patient-reported outcome (present or absent).
All participants had antegrade ejaculation at baseline as an eligibility requirement.
|
3 months after surgery
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Durability of integrate ejaculation preservation
Délai: 6 and 12 months after surgery
|
Proportion of participants reporting presence of any antegrade ejaculate, assessed as for the primary outcome, to test whether any benefit is sustained over time.
|
6 and 12 months after surgery
|
|
Change in international prostate symptom score IPSS
Délai: Baseline, 3, 6, and 12 months after surgery
|
IPSS total score, range 0 to 35, where higher scores indicate more severe lower urinary tract symptoms.
Change from baseline is reported.
|
Baseline, 3, 6, and 12 months after surgery
|
|
Change in IPSS quality of life score
Délai: Baseline, 3, 6, and 12 months after surgery
|
Single-item IPSS quality-of-life question, range 0 to 6, where higher scores indicate worse bother from urinary symptoms.
|
Baseline, 3, 6, and 12 months after surgery
|
|
Change in maximum urinary flow rate (Qmax)
Délai: Baseline, 3, 6, and 12 months after surgery
|
Maximum flow rate in mL/s measured by uroflowmetry, accepted only when voided volume was at least 150 mL.
Higher values indicate better flow.
|
Baseline, 3, 6, and 12 months after surgery
|
|
Change in post-void residual urine volume
Délai: Baseline, 3, 6, and 12 months after surgery
|
Post-void residual volume in mL measured by transabdominal ultrasound.
Lower values indicate more complete bladder emptying.
|
Baseline, 3, 6, and 12 months after surgery
|
|
Change in prostate volume
Délai: Baseline, 3, 6, and 12 months after surgery
|
prostate volume in cc measured by transabdominal ultrasound, using the prolate, elipsoid formula with percentage reduction from baseline calculated
|
Baseline, 3, 6, and 12 months after surgery
|
|
Change in erectile function (IIEF-5)
Délai: Baseline, 3, 6, and 12 months after surgery
|
Five-item International Index of Erectile Function, range 5 to 25, where higher scores indicate better erectile function.
Assessed as a control variable to distinguish ejaculatory from erectile outcomes.
Face like, three, six, and 12 months after
|
Baseline, 3, 6, and 12 months after surgery
|
|
Complications graded by Clavien-Dindo classification
Délai: From surgery to 12 months after surgery
|
Clavien-Dindo grade recorded per participant, from grade I (any deviation from normal course) to grade V (death), including in-hospital and all follow-up intervals.
|
From surgery to 12 months after surgery
|
|
Patient global satisfaction
Délai: 3, 6, and 12 months after surgery
|
Patient-reported global satisfaction with the outcome of surgery on a 5-point scale, where 1 indicates very dissatisfied and 5 indicates very satisfied.
|
3, 6, and 12 months after surgery
|
|
Trifecta outcome
Délai: 12 months after surgery
|
Composite endpoint requiring all three of: IPSS below 8, complete pad independence, and preserved antegrade ejaculation.
|
12 months after surgery
|
|
Operative time, catheterization time and hospital stay
Délai: Day of surgery to hospital discharge, up to seven days
|
Operative time in minutes measured from insertion to withdrawal of the cystoscope, duration of postoperative catheterisation in hours, and length of hospital stay in hours.
|
Day of surgery to hospital discharge, up to seven days
|
|
Early post operative dysuria
Délai: Day 7 to 14 and 1month after surgery
|
Dysuria severity on a visual analogue scale from 0 to 10, where higher scores indicate more severe dysuria, together with the duration of dysuria in days.
|
Day 7 to 14 and 1month after surgery
|
|
Re-treatment for benign prostatic obstruction
Délai: Up to 12 months after surgery
|
Proportion of participants requiring any further surgical intervention for benign prostatic obstruction.
|
Up to 12 months after surgery
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Publications générales
- Emam A, Nabil Habib K, Teama K, Samir Y, Sadeq MM, Gamal MA. "Laser vaporization of the prostate: A comparative study between ejaculatory preserving and non-ejaculatory preserving technique". Arab J Urol. 2024 Jul 4;23(1):8-15. doi: 10.1080/20905998.2024.2375677. eCollection 2025.
- Ramez M, Abolazm AE, El-Nahas AR. Ejaculatory-sparing transurethral prostatectomy: a meta-analysis of randomized controlled trials. Sex Med Rev. 2024 Sep 25;12(4):754-760. doi: 10.1093/sxmrev/qeae054.
- Abolazm AE, El-Hefnawy AS, Laymon M, Shehab-El-Din AB, Elshal AM. Ejaculatory Hood Sparing versus Standard Laser Photoselective Vaporization of the Prostate: Sexual and Urodynamic Assessment through a Double Blinded, Randomized Trial. J Urol. 2020 Apr;203(4):792-801. doi: 10.1097/JU.0000000000000685. Epub 2019 Nov 25.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies génitales
- Dysfonctionnement éjaculatoire
- Maladies génitales, sexe masculin
- Maladies de la prostate
- Maladies urogénitales masculines
- Maladies urologiques
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Maladies de la vessie urinaire
- Dysfonction sexuelle, physiologique
- Maladies urétrales
- Obstruction urétrale
- Hyperplasie prostatique
- Obstruction du col de la vessie urinaire
- Retrograde Ejaculation
Autres numéros d'identification d'étude
- UOS-COM-62-2024
- UOS-COM-ETHICS-62 (Autre identifiant: Ethics Committee, College of Medicine, University of Sulaimani)
- UOS-CSD-REG-28 (Autre identifiant: Clinical Sciences Department Scientific Committee, University of Sulaimani)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Délai de partage IPD
Critères d'accès au partage IPD
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .